Using symptom-based case predictions to identify host genetic factors that contribute to COVID-19 susceptibility
Epidemiological and genetic studies on COVID-19 are currently hindered by inconsistent and limited testing policies to confirm SARS-CoV-2 infection. Recently, it was shown that it is possible to predict COVID-19 cases using cross-sectional self-reported disease-related symptoms. Here, we demonstrate that this COVID-19 prediction model has reasonable and consistent performance across multiple independent cohorts and that our attempt to improve upon this model did not result in improved predictions. Using the existing COVID-19 prediction model, we then conducted a GWAS on the predicted phenotype using a total of 1,865 predicted cases and 29,174 controls. While we did not find any common, large-effect variants that reached genome-wide significance, we do observe suggestive genetic associations at two SNPs (rs11844522, p = 1.9x10-7; rs5798227, p = 2.2x10-7). Explorative analyses furthermore suggest that genetic variants associated with other viral infectious diseases do not overlap with COVID-19 susceptibility and that severity of COVID-19 may have a different genetic architecture compared to COVID-19 susceptibility. This study represents a first effort that uses a symptom-based predicted phenotype as a proxy for COVID-19 in our pursuit of understanding the genetic susceptibility of the disease. We conclude that the inclusion of symptom-based predicted cases could be a useful strategy in a scenario of limited testing, either during the current COVID-19 pandemic or any future viral outbreak..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
PLoS ONE - 16(2021), 8 |
| Sprache: |
Englisch |
|---|
| Links: |
doaj.org [kostenfrei] |
|---|
| Themen: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ00297164X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ00297164X | ||
| 003 | DE-627 | ||
| 005 | 20230503151409.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ00297164X | ||
| 035 | |a (DE-599)DOAJ48e7e653327e48aabd22b8438d85070f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Irene V. van Blokland |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Using symptom-based case predictions to identify host genetic factors that contribute to COVID-19 susceptibility |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Epidemiological and genetic studies on COVID-19 are currently hindered by inconsistent and limited testing policies to confirm SARS-CoV-2 infection. Recently, it was shown that it is possible to predict COVID-19 cases using cross-sectional self-reported disease-related symptoms. Here, we demonstrate that this COVID-19 prediction model has reasonable and consistent performance across multiple independent cohorts and that our attempt to improve upon this model did not result in improved predictions. Using the existing COVID-19 prediction model, we then conducted a GWAS on the predicted phenotype using a total of 1,865 predicted cases and 29,174 controls. While we did not find any common, large-effect variants that reached genome-wide significance, we do observe suggestive genetic associations at two SNPs (rs11844522, p = 1.9x10-7; rs5798227, p = 2.2x10-7). Explorative analyses furthermore suggest that genetic variants associated with other viral infectious diseases do not overlap with COVID-19 susceptibility and that severity of COVID-19 may have a different genetic architecture compared to COVID-19 susceptibility. This study represents a first effort that uses a symptom-based predicted phenotype as a proxy for COVID-19 in our pursuit of understanding the genetic susceptibility of the disease. We conclude that the inclusion of symptom-based predicted cases could be a useful strategy in a scenario of limited testing, either during the current COVID-19 pandemic or any future viral outbreak. | ||
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 700 | 0 | |a Pauline Lanting |e verfasserin |4 aut | |
| 700 | 0 | |a Anil P. S. Ori |e verfasserin |4 aut | |
| 700 | 0 | |a Judith M. Vonk |e verfasserin |4 aut | |
| 700 | 0 | |a Robert C. A. Warmerdam |e verfasserin |4 aut | |
| 700 | 0 | |a Johanna C. Herkert |e verfasserin |4 aut | |
| 700 | 0 | |a Floranne Boulogne |e verfasserin |4 aut | |
| 700 | 0 | |a Annique Claringbould |e verfasserin |4 aut | |
| 700 | 0 | |a Esteban A. Lopera-Maya |e verfasserin |4 aut | |
| 700 | 0 | |a Meike Bartels |e verfasserin |4 aut | |
| 700 | 0 | |a Jouke-Jan Hottenga |e verfasserin |4 aut | |
| 700 | 0 | |a Andrea Ganna |e verfasserin |4 aut | |
| 700 | 0 | |a Juha Karjalainen |e verfasserin |4 aut | |
| 700 | 0 | |a Lifelines COVID-19 cohort study |e verfasserin |4 aut | |
| 700 | 0 | |a The COVID-19 Host Genetics Initiative |e verfasserin |4 aut | |
| 700 | 0 | |a Caroline Hayward |e verfasserin |4 aut | |
| 700 | 0 | |a Chloe Fawns-Ritchie |e verfasserin |4 aut | |
| 700 | 0 | |a Archie Campbell |e verfasserin |4 aut | |
| 700 | 0 | |a David Porteous |e verfasserin |4 aut | |
| 700 | 0 | |a Elizabeth T. Cirulli |e verfasserin |4 aut | |
| 700 | 0 | |a Kelly M. Schiabor Barrett |e verfasserin |4 aut | |
| 700 | 0 | |a Stephen Riffle |e verfasserin |4 aut | |
| 700 | 0 | |a Alexandre Bolze |e verfasserin |4 aut | |
| 700 | 0 | |a Simon White |e verfasserin |4 aut | |
| 700 | 0 | |a Francisco Tanudjaja |e verfasserin |4 aut | |
| 700 | 0 | |a Xueqing Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Jimmy M. Ramirez |e verfasserin |4 aut | |
| 700 | 0 | |a Yan Wei Lim |e verfasserin |4 aut | |
| 700 | 0 | |a James T. Lu |e verfasserin |4 aut | |
| 700 | 0 | |a Nicole L. Washington |e verfasserin |4 aut | |
| 700 | 0 | |a Eco J. C. de Geus |e verfasserin |4 aut | |
| 700 | 0 | |a Patrick Deelen |e verfasserin |4 aut | |
| 700 | 0 | |a H. Marike Boezen |e verfasserin |4 aut | |
| 700 | 0 | |a Lude H. Franke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t PLoS ONE |d Public Library of Science (PLoS), 2007 |g 16(2021), 8 |w (DE-627)DOAJ000113018 |x 19326203 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g number:8 |
| 856 | 4 | 0 | |u https://doaj.org/article/48e7e653327e48aabd22b8438d85070f |z kostenfrei |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357137/?tool=EBI |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1932-6203 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2021 |e 8 | ||